Clinical Trial Update: Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease [Phase 1, Phase 2]

View source ↗

Summary

CRISPR Therapeutics reports safety data and preliminary efficacy signals for CTX112 in adults with relapsed/refractory warm autoimmune hemolytic anemia and immu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• CTX112

Snippet

Sponsor: CRISPR Therapeutics AG | Conditions: Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING